215 related articles for article (PubMed ID: 37460547)
1. Context-defined cancer co-dependency mapping identifies a functional interplay between PRC2 and MLL-MEN1 complex in lymphoma.
Chen X; Li Y; Zhu F; Xu X; Estrella B; Pazos MA; McGuire JT; Karagiannis D; Sahu V; Mustafokulov M; Scuoppo C; Sánchez-Rivera FJ; Soto-Feliciano YM; Pasqualucci L; Ciccia A; Amengual JE; Lu C
Nat Commun; 2023 Jul; 14(1):4259. PubMed ID: 37460547
[TBL] [Abstract][Full Text] [Related]
2. IMITATION SWITCH is required for normal chromatin structure and gene repression in PRC2 target domains.
Kamei M; Ameri AJ; Ferraro AR; Bar-Peled Y; Zhao F; Ethridge CL; Lail K; Amirebrahimi M; Lipzen A; Ng V; Grigoriev IV; Schmitz RJ; Liu Y; Lewis ZA
Proc Natl Acad Sci U S A; 2021 Jan; 118(4):. PubMed ID: 33468665
[TBL] [Abstract][Full Text] [Related]
3. Not just a writer: PRC2 as a chromatin reader.
Uckelmann M; Davidovich C
Biochem Soc Trans; 2021 Jun; 49(3):1159-1170. PubMed ID: 34060617
[TBL] [Abstract][Full Text] [Related]
4. Structural basis for PRC2 engagement with chromatin.
Glancy E; Ciferri C; Bracken AP
Curr Opin Struct Biol; 2021 Apr; 67():135-144. PubMed ID: 33232890
[TBL] [Abstract][Full Text] [Related]
5. The JAZF1-SUZ12 fusion protein disrupts PRC2 complexes and impairs chromatin repression during human endometrial stromal tumorogenesis.
Ma X; Wang J; Wang J; Ma CX; Gao X; Patriub V; Sklar JL
Oncotarget; 2017 Jan; 8(3):4062-4078. PubMed ID: 27845897
[TBL] [Abstract][Full Text] [Related]
6. Chromatin regulator PRC2 is a key regulator of epigenetic plasticity in glioblastoma.
Natsume A; Ito M; Katsushima K; Ohka F; Hatanaka A; Shinjo K; Sato S; Takahashi S; Ishikawa Y; Takeuchi I; Shimogawa H; Uesugi M; Okano H; Kim SU; Wakabayashi T; Issa JP; Sekido Y; Kondo Y
Cancer Res; 2013 Jul; 73(14):4559-70. PubMed ID: 23720055
[TBL] [Abstract][Full Text] [Related]
7. EZH2 variants differentially regulate polycomb repressive complex 2 in histone methylation and cell differentiation.
Mu W; Starmer J; Yee D; Magnuson T
Epigenetics Chromatin; 2018 Dec; 11(1):71. PubMed ID: 30522506
[TBL] [Abstract][Full Text] [Related]
8. Polycomb Gene Silencing Mechanisms: PRC2 Chromatin Targeting, H3K27me3 'Readout', and Phase Separation-Based Compaction.
Guo Y; Zhao S; Wang GG
Trends Genet; 2021 Jun; 37(6):547-565. PubMed ID: 33494958
[TBL] [Abstract][Full Text] [Related]
9. Dissecting the role of H3K27 acetylation and methylation in PRC2 mediated control of cellular identity.
Lavarone E; Barbieri CM; Pasini D
Nat Commun; 2019 Apr; 10(1):1679. PubMed ID: 30976011
[TBL] [Abstract][Full Text] [Related]
10. Targeting Excessive EZH1 and EZH2 Activities for Abnormal Histone Methylation and Transcription Network in Malignant Lymphomas.
Yamagishi M; Hori M; Fujikawa D; Ohsugi T; Honma D; Adachi N; Katano H; Hishima T; Kobayashi S; Nakano K; Nakashima M; Iwanaga M; Utsunomiya A; Tanaka Y; Okada S; Tsukasaki K; Tobinai K; Araki K; Watanabe T; Uchimaru K
Cell Rep; 2019 Nov; 29(8):2321-2337.e7. PubMed ID: 31747604
[TBL] [Abstract][Full Text] [Related]
11. Targeting EZH2 and PRC2 dependence as novel anticancer therapy.
Xu B; Konze KD; Jin J; Wang GG
Exp Hematol; 2015 Aug; 43(8):698-712. PubMed ID: 26027790
[TBL] [Abstract][Full Text] [Related]
12. Histone variants H2A.Z and H3.3 coordinately regulate PRC2-dependent H3K27me3 deposition and gene expression regulation in mES cells.
Wang Y; Long H; Yu J; Dong L; Wassef M; Zhuo B; Li X; Zhao J; Wang M; Liu C; Wen Z; Chang L; Chen P; Wang QF; Xu X; Margueron R; Li G
BMC Biol; 2018 Sep; 16(1):107. PubMed ID: 30249243
[TBL] [Abstract][Full Text] [Related]
13. Polycomb repressive complex 2 epigenomic signature defines age-associated hypermethylation and gene expression changes.
Dozmorov MG
Epigenetics; 2015; 10(6):484-95. PubMed ID: 25880792
[TBL] [Abstract][Full Text] [Related]
14. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations.
McCabe MT; Ott HM; Ganji G; Korenchuk S; Thompson C; Van Aller GS; Liu Y; Graves AP; Della Pietra A; Diaz E; LaFrance LV; Mellinger M; Duquenne C; Tian X; Kruger RG; McHugh CF; Brandt M; Miller WH; Dhanak D; Verma SK; Tummino PJ; Creasy CL
Nature; 2012 Dec; 492(7427):108-12. PubMed ID: 23051747
[TBL] [Abstract][Full Text] [Related]
15. Polycomb repressive complex 2 is required for MLL-AF9 leukemia.
Neff T; Sinha AU; Kluk MJ; Zhu N; Khattab MH; Stein L; Xie H; Orkin SH; Armstrong SA
Proc Natl Acad Sci U S A; 2012 Mar; 109(13):5028-33. PubMed ID: 22396593
[TBL] [Abstract][Full Text] [Related]
16. EZH2 W113C is a gain-of-function mutation in B-cell lymphoma enabling both PRC2 methyltransferase activation and tazemetostat resistance.
Chu L; Tan D; Zhu M; Qu Y; Ma X; Song BL; Qi W
J Biol Chem; 2023 Apr; 299(4):103073. PubMed ID: 36858198
[TBL] [Abstract][Full Text] [Related]
17. Jarid2 Methylation via the PRC2 Complex Regulates H3K27me3 Deposition during Cell Differentiation.
Sanulli S; Justin N; Teissandier A; Ancelin K; Portoso M; Caron M; Michaud A; Lombard B; da Rocha ST; Offer J; Loew D; Servant N; Wassef M; Burlina F; Gamblin SJ; Heard E; Margueron R
Mol Cell; 2015 Mar; 57(5):769-783. PubMed ID: 25620564
[TBL] [Abstract][Full Text] [Related]
18. The H3K36me2 Methyltransferase Nsd1 Demarcates PRC2-Mediated H3K27me2 and H3K27me3 Domains in Embryonic Stem Cells.
Streubel G; Watson A; Jammula SG; Scelfo A; Fitzpatrick DJ; Oliviero G; McCole R; Conway E; Glancy E; Negri GL; Dillon E; Wynne K; Pasini D; Krogan NJ; Bracken AP; Cagney G
Mol Cell; 2018 Apr; 70(2):371-379.e5. PubMed ID: 29606589
[TBL] [Abstract][Full Text] [Related]
19. Jarid2 binds mono-ubiquitylated H2A lysine 119 to mediate crosstalk between Polycomb complexes PRC1 and PRC2.
Cooper S; Grijzenhout A; Underwood E; Ancelin K; Zhang T; Nesterova TB; Anil-Kirmizitas B; Bassett A; Kooistra SM; Agger K; Helin K; Heard E; Brockdorff N
Nat Commun; 2016 Nov; 7():13661. PubMed ID: 27892467
[TBL] [Abstract][Full Text] [Related]
20. Inactivation of Eed impedes MLL-AF9-mediated leukemogenesis through Cdkn2a-dependent and Cdkn2a-independent mechanisms in a murine model.
Danis E; Yamauchi T; Echanique K; Haladyna J; Kalkur R; Riedel S; Zhu N; Xie H; Bernt KM; Orkin SH; Armstrong SA; Neff T
Exp Hematol; 2015 Nov; 43(11):930-935.e6. PubMed ID: 26118502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
